Close Menu
  • Home
  • Technology
  • Devices
  • Business
  • Science
  • Gadgets
  • Startups
Ayaksız
  • Home
  • Technology

    Lucid and Bolt Plan 25,000 Robotaxis for Europe

    Eylül 18, 2026

    AMD Gives PC Builders More Choice With New Ryzen 5 Desktop Chips

    Eylül 11, 2026

    Apple Expands Device Protection With a $49.99 Family Plan

    Eylül 11, 2026

    Snapdragon 8 Elite Extreme Gen 6 Reportedly Beats MediaTek’s Next Flagship Chipset

    Eylül 11, 2026

    Pinterest CFO Julia Donnelly to Step Down in October

    Ağustos 30, 2026
  • Devices

    Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone

    Kasım 18, 2026

    Router Mode or Access Point Mode? Give Each Network Device a Clear Job

    Kasım 18, 2026

    Scanner Feeder or Glass? Choose According to the Original

    Kasım 13, 2026

    Borderless Printing: Why the Edges of Your Photo Can Disappear

    Kasım 12, 2026

    Camera AE Lock: Recompose a Scene Without Letting Exposure Drift

    Kasım 11, 2026
  • Business

    Google Pixel 11 Pro Leaked Renders Indicate It Might Sport Thinner Bezels Than the Pixel 10 Pro

    Mart 30, 2026

    Motorola Edge 70 Debuts With Snapdragon 7 Gen 4, Ultra-Slim 5.99mm Body

    Kasım 5, 2025

    Samsung Galaxy S26 Series Could See Price Increase Amid Rising Component Costs: Report

    Kasım 4, 2025

    Amazon’s AWS Partners with NBA to Power New AI Basketball Platform

    Ekim 4, 2025

    Billionaire-Backed Bitcoin Firm OranjeBTC to List on Brazil’s B3 Exchange

    Ekim 4, 2025
  • Science

    Double Rainbows: Why the Outer Arc Reverses Its Colors

    Kasım 18, 2026

    Why Ice Floats—and Why Water Behaves Differently Near Freezing

    Kasım 13, 2026

    Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

    Kasım 12, 2026

    A Light-Year Measures Distance: Understanding the Scale Behind Space Headlines

    Kasım 11, 2026

    Why the Sky Is Blue—and Why the Same Atmosphere Produces Red Sunsets

    Kasım 10, 2026
  • Gadgets

    Tripod Center Columns: Extra Height Comes with a Stability Tradeoff

    Kasım 18, 2026

    E Ink Ghosting: Match the Refresh Mode to the Task

    Kasım 13, 2026

    Camera Lens Hoods: Choose the Right Shape and Check the Whole Frame

    Kasım 12, 2026

    Pop Filters and Windscreens: Match Microphone Protection to the Noise

    Kasım 12, 2026

    USB Hub Power: Check Where Your Connected Devices Get Their Energy

    Kasım 11, 2026
  • Startups

    Cache-Control for Startups: No-Cache and No-Store Solve Different Problems

    Kasım 18, 2026

    Dead-Letter Queues: Investigate Before Replaying Failed Messages

    Kasım 13, 2026

    Database Connection Pools: Budget Across Every Application Replica

    Kasım 13, 2026

    Startup Staging Sites: Separate Search Visibility from Access Control

    Kasım 12, 2026

    API Idempotency Keys: Keep a Retry Connected to the Original Operation

    Kasım 11, 2026
Ayaksız
Anasayfa » Blog » Medicaid Dominates U.S. Coverage for Novo Nordisk and Eli Lilly Weight-Loss Drugs
Science

Medicaid Dominates U.S. Coverage for Novo Nordisk and Eli Lilly Weight-Loss Drugs

By ayaksızKasım 18, 2024Yorum yapılmamış3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Government Programs Drive Access to GLP-1 Drugs

State Medicaid programs and federal employee health plans are the leading sources of coverage for popular new weight-loss drugs, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. According to data from the AXIACI Obesity Coverage Nexus, government-funded plans provide access to these treatments for over 52 million Americans, significantly outpacing private employer and commercial insurance coverage.

Coverage Breakdown:

  • Medicaid Programs: Cover 31.6 million low-income individuals.
  • Federal Employee Plans: Provide access to 14.6 million federal workers and dependents.
  • State and Local Employee Plans: Cover an additional 6 million individuals.

In contrast, approximately 13.7 million Americans under commercial health plans have coverage for these drugs. An additional estimated 10.7 million privately insured individuals may also have coverage, bringing the total private sector figure to a potential 24.4 million—still less than half of government-backed coverage.


Barriers to Broader Coverage

The discrepancy between public and private plans highlights employer hesitancy to absorb the costs of GLP-1 drugs, which carry list prices exceeding $1,000 per month. Kathy Hempstead of the Robert Wood Johnson Foundation attributes this to rising health insurance premiums, which make funding weight-loss treatments an added challenge for private employers.

Many private insurers impose stringent prerequisites, such as dietary consultations or lifestyle programs, before approving coverage. Additionally, patients often face limited drug availability and may turn to cheaper alternatives from compounding pharmacies.


Impact on Drugmakers and Patients

While Medicaid’s steep drug price discounts may affect Novo Nordisk and Eli Lilly’s profit margins, higher obesity rates among Medicaid recipients present a significant market opportunity. For many patients, insurance coverage is the only feasible way to access these expensive medications, which can be required for long-term use.

Both companies are lobbying for broader insurance coverage, emphasizing the societal cost savings from reducing obesity-related conditions like heart disease and diabetes. Novo estimates that about half of U.S. adults with obesity now have access to weight-loss medications. However, Lilly acknowledges gaps in commercial insurance coverage, citing ongoing stigma and mismanagement of obesity as barriers to treatment.


State-by-State Medicaid Approaches

Currently, 14 state Medicaid programs, including California, Pennsylvania, and North Carolina, offer coverage for GLP-1 drugs to treat obesity. Seventeen states extend coverage to public employees and their dependents, with five—Connecticut, Delaware, Kansas, Massachusetts, and Michigan—offering both.

Medicare, the federal program for individuals 65 and older, does not cover GLP-1 drugs for weight loss, limiting its use to managing type 2 diabetes and cardiovascular disease.

Christine Ferguson, a healthcare policy expert, noted the fragmented nature of state decisions on coverage, saying, “Everyone is being very cautious here,” with no clear national pattern emerging yet.


Future of GLP-1 Coverage

As the use of GLP-1 receptor agonists continues to reshape obesity treatment in the U.S., the divide between public and private insurance coverage underscores ongoing challenges in integrating weight-loss drugs into broader healthcare frameworks. Drugmakers are likely to intensify advocacy efforts for expanded insurance support, seeking to address both financial and cultural barriers to care.

Eli Lilly GLP-1 Drugs Insurance Gaps Medicaid Coverage Novo Nordisk Obesity Treatment Wegovy Weight Loss Drugs Zepbound
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
ayaksız
  • Website

Related Posts

Double Rainbows: Why the Outer Arc Reverses Its Colors

Kasım 18, 2026

Why Ice Floats—and Why Water Behaves Differently Near Freezing

Kasım 13, 2026

Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

Kasım 12, 2026
Add A Comment

Comments are closed.

Recent Posts
  • Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone
  • Cache-Control for Startups: No-Cache and No-Store Solve Different Problems
  • Tripod Center Columns: Extra Height Comes with a Stability Tradeoff
  • Double Rainbows: Why the Outer Arc Reverses Its Colors
  • Router Mode or Access Point Mode? Give Each Network Device a Clear Job
Tags
AI AI Chips AI Infrastructure Amazon Android Apple Artificial Intelligence Bitcoin ChatGPT China Cryptocurrency Cybersecurity data centers DeepSeek Donald Trump Electric Vehicles Elon Musk Ether Generative AI Google Huawei India Investment Iphone Meta Microsoft NASA National Security Nvidia OnePlus OpenAI Oppo Realme Samsung semiconductor industry Social media Sony SpaceX Technology Tesla Tether TikTok Vivo WhatsApp Xiaomi
Ayaksız
Instagram
© 2026 Ayaksız.

Type above and press Enter to search. Press Esc to cancel.